{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:23Z","timestamp":1792787303723,"version":"4.5.0"},"reference-count":26,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"unspecified","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Instituto de Salud Carlos III","award":["PI23\/00046"],"award-info":[{"award-number":["PI23\/00046"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2026,9,17]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Interleukin-22 (IL-22), a member of the IL-10 cytokine family, primarily targets non-haematopoietic epithelial and stromal cells, contributing to maintenance of epithelial barrier integrity, antimicrobial immunity and tissue regeneration. In this study, we sought to evaluate the association between serum levels of IL-22, measured by an ultrasensitive assay, and disease characteristics in patients with SLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cross-sectional study, we thoroughly assessed 313 patients with SLE, collecting data on autoantibody status as well as disease activity indices (SLE Disease Activity Index-2000 and Lupus Low Disease Activity State), damage accrual (Systemic Lupus International Collaborating Clinics\/American College of Rheumatology Damage Index (SLICC-DI)) and remission status (Definitions of Remission in SLE). The cohort was also characterised in terms of haematological parameters, lipid profile, insulin resistance markers and measures of subclinical carotid atherosclerosis and arterial stiffness. Serum IL-22 concentrations were quantified using the Simoa (Single Molecule Array) platform. We then used multivariable linear regression to explore the associations between these clinical characteristics and circulating IL-22 levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After multivariable adjustment, serum IL-22 levels were independently linked to longer disease duration, cumulative damage (SLICC-DI &gt;1) and inversely to methotrexate use. However, these associations did not remain significant after multiple comparison correction. Disease activity, autoantibody profile or complement and interferon levels did not show significant associations with IL-22 levels. Similarly, haematological parameters were not related to circulating IL-22. Regarding cardiovascular risk factors, IL-22 was inversely related to high-density lipoprotein-cholesterol and apolipoprotein A1 suggesting an adverse lipid profile. In addition, serum C-peptide levels were independently related to higher circulating IL-22 concentrations whereas the presence of metabolic syndrome was associated with increased IL-22 levels. Besides, carotid intima-media thickness was significantly correlated with superior IL-22 levels after adjustment for covariates although in this case this association did not withstand adjustment for multiple testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with SLE, IL-22 identifies a phenotype of increased cardiovascular risk despite showing little relationship with current disease activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2026-002217","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:45:08Z","timestamp":1790693108000},"page":"e002217","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Interleukin-22 reflects adverse cardiometabolic features in SLE"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-5267","authenticated-orcid":false,"given":"Iv\u00e1n","family":"Ferraz-Amaro","sequence":"first","affiliation":[{"name":"Instituto de Investigaciones Sanitarias de Canarias (IISC), Tenerife, Spain"},{"name":"Departamento de Medicina Interna, Universidad de La Laguna (ULL), Tenerife, Spain"},{"name":"Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Quevedo-Abeledo","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario Insulsar Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Tejera Segura","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Garc\u00eda-Barrera","sequence":"additional","affiliation":[{"name":"Division of Immunology, Hospital Universitario Ramon y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Mar\u00eda","family":"Villar","sequence":"additional","affiliation":[{"name":"Division of Immunology, Hospital Universitario Ramon y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Gonzalo","family":"Ocejo-Vinyals","sequence":"additional","affiliation":[{"name":"Division of Immunology, Marquis of Valdecilla University Hospital, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-2944","authenticated-orcid":false,"given":"Raquel","family":"Largo","sequence":"additional","affiliation":[{"name":"Joint and Bone Research Unit, Rheumatology Department, Jimenez Diaz Foundation University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7924-7406","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Gonzalez-Gay","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Jimenez Diaz Foundation University Hospital, Madrid, Spain"},{"name":"Department of Medicine and Psychiatry, University of Cantabria, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"2026092908103158000_13.2.e002217.1","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201201374"},{"key":"2026092908103158000_13.2.e002217.2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12027"},{"key":"2026092908103158000_13.2.e002217.3","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-020-00504-1","article-title":"Interleukin-22 and connective tissue diseases: emerging role in pathogenesis and therapy","volume":"11","author":"Xuan","year":"2021","journal-title":"Cell Biosci"},{"key":"2026092908103158000_13.2.e002217.4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.584414","article-title":"Interleukin-22 From Type 3 Innate Lymphoid Cells Aggravates Lupus Nephritis by Promoting Macrophage Infiltration in Lupus-Prone Mice","volume":"12","author":"Hu","year":"2021","journal-title":"Front Immunol"},{"key":"2026092908103158000_13.2.e002217.5","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12135"},{"key":"2026092908103158000_13.2.e002217.6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-01939-7","article-title":"Plasma interleukin-22 concentration and disease activity in inflammatory bowel disease","volume":"15","author":"Cabrera","year":"2025","journal-title":"Sci Rep"},{"key":"2026092908103158000_13.2.e002217.7","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2026092908103158000_13.2.e002217.8","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2026092908103158000_13.2.e002217.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303"},{"key":"2026092908103158000_13.2.e002217.10","first-page":"S","article-title":"Assessing remission in systemic lupus erythematosus","volume":"24","author":"Mosca","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"2026092908103158000_13.2.e002217.11","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026092908103158000_13.2.e002217.12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/acr.23109","article-title":"Defining Low Disease Activity in Systemic Lupus Erythematosus","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026092908103158000_13.2.e002217.13","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.6.1487"},{"key":"2026092908103158000_13.2.e002217.14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"2026092908103158000_13.2.e002217.15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab309"},{"key":"2026092908103158000_13.2.e002217.16","doi-asserted-by":"publisher","DOI":"10.1159\/000343145"},{"key":"2026092908103158000_13.2.e002217.17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl254"},{"key":"2026092908103158000_13.2.e002217.18","doi-asserted-by":"publisher","DOI":"10.1177\/1535370213477597"},{"key":"2026092908103158000_13.2.e002217.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13344-w","article-title":"Elevated levels of CCR6+ T helper 22 cells correlate with skin and renal impairment in systemic lupus erythematosus","volume":"7","author":"Zhong","year":"2017","journal-title":"Sci Rep"},{"key":"2026092908103158000_13.2.e002217.20","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keag235","article-title":"High-sensitivity serum interferon-\u03b1 and interferon-\u03b3 as immunometabolic mediators of metabolic syndrome in systemic lupus erythematosus","volume":"65","author":"Gonz\u00e1lez-Gay","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"2026092908103158000_13.2.e002217.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-017-0498-6","article-title":"Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4\/FF4 study","volume":"16","author":"Herder","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2026092908103158000_13.2.e002217.22","doi-asserted-by":"crossref","first-page":"111776","DOI":"10.1016\/j.mce.2022.111776","article-title":"Down-regulating Interleukin-22\/Interleukin-22 binding protein axis promotes inflammation and aggravates diet-induced metabolic disorders","volume":"557","author":"Gu","year":"2022","journal-title":"Mol Cell Endocrinol"},{"key":"2026092908103158000_13.2.e002217.23","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1111\/jcmm.14967","article-title":"IL-22 produced by Th22 cells aggravates atherosclerosis development in ApoE-\/- mice by enhancing DC-induced Th17 cell proliferation","volume":"24","author":"Shi","year":"2020","journal-title":"J Cell Mol Med"},{"key":"2026092908103158000_13.2.e002217.24","doi-asserted-by":"crossref","DOI":"10.1186\/s10020-021-00353-9","article-title":"Interleukin-22: a potential therapeutic target in atherosclerosis","volume":"27","author":"Luo","year":"2021","journal-title":"Mol Med"},{"key":"2026092908103158000_13.2.e002217.25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085770","article-title":"Elevated peripheral frequencies of Th22 cells: a novel potent participant in obesity and type 2 diabetes","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"key":"2026092908103158000_13.2.e002217.26","first-page":"885","article-title":"Insulin resistance in systemic lupus erythematosus patients: contributing factors and relationship with subclinical atherosclerosis","volume":"35","author":"S\u00e1nchez-P\u00e9rez","year":"2017","journal-title":"Clin Exp Rheumatol"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2026-002217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:15:21Z","timestamp":1790694921000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2026-002217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,9,29]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/lupus-2026-002217"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2026-002217","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}